28331 Search Results


klebsiella pneumoniae atcc  (ATCC)
93
ATCC klebsiella pneumoniae atcc
Klebsiella Pneumoniae Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/klebsiella pneumoniae atcc/product/ATCC
Average 93 stars, based on 1 article reviews
klebsiella pneumoniae atcc - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
pc2  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology pc2
Pc2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pc2/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
pc2 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
il4r polyclonal antibody  (Proteintech)
93
Proteintech il4r polyclonal antibody
Inhibition of immunoproteasome (IP) increases IL-4Rα and eotaxin-3 in IL-13-stimulated human airway epithelial cells. Tracheobronchial epithelial cells from n=6 healthy donors were pre-treated with immunoproteasome LMP7 inhibitor ONX-0914, then given anti-IL4Rα antibody followed by IL-13 treatment. IP inhibition in IL-13 treated cells significantly upregulated IL-4Rα protein levels five hours after ONX-0914 treatment (A) , as well as significantly increased eotaxin-3 levels after 72 hours (B) . Anti-IL4Rα antibody significantly inhibited IL-13-induced eotaxin-3.
Il4r Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il4r polyclonal antibody/product/Proteintech
Average 93 stars, based on 1 article reviews
il4r polyclonal antibody - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

Image Search Results


Inhibition of immunoproteasome (IP) increases IL-4Rα and eotaxin-3 in IL-13-stimulated human airway epithelial cells. Tracheobronchial epithelial cells from n=6 healthy donors were pre-treated with immunoproteasome LMP7 inhibitor ONX-0914, then given anti-IL4Rα antibody followed by IL-13 treatment. IP inhibition in IL-13 treated cells significantly upregulated IL-4Rα protein levels five hours after ONX-0914 treatment (A) , as well as significantly increased eotaxin-3 levels after 72 hours (B) . Anti-IL4Rα antibody significantly inhibited IL-13-induced eotaxin-3.

Journal: Frontiers in Immunology

Article Title: Degradation of IL-4Ralpha by Immunoproteasome: implication in airway type 2 inflammation and hyperresponsiveness

doi: 10.3389/fimmu.2025.1501898

Figure Lengend Snippet: Inhibition of immunoproteasome (IP) increases IL-4Rα and eotaxin-3 in IL-13-stimulated human airway epithelial cells. Tracheobronchial epithelial cells from n=6 healthy donors were pre-treated with immunoproteasome LMP7 inhibitor ONX-0914, then given anti-IL4Rα antibody followed by IL-13 treatment. IP inhibition in IL-13 treated cells significantly upregulated IL-4Rα protein levels five hours after ONX-0914 treatment (A) , as well as significantly increased eotaxin-3 levels after 72 hours (B) . Anti-IL4Rα antibody significantly inhibited IL-13-induced eotaxin-3.

Article Snippet: Equal amounts of proteins were loaded and separated by SDS-PAGE, transferred onto PVDF membranes, blocked with blocking buffer, and incubated with the following primary antibodies overnight at 4°C: IL4R Polyclonal antibody (Anti-human, Proteintech Group, Inc., Rosemont, IL), LMP2 (Abcam, Cambridge, United Kingdom), LMP7 (Proteintech Group Inc. Rosemont, IL), IL-4Rα Antibody (Anti-mouse, Santa Cruz Biotechnology, Dallas, TX), and Beta-Actin antibody (Santa Cruz Biotechnology, Dallas, TX).

Techniques: Inhibition